Clinical trialNCT02444793TerminatedPhase 1Interventional

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

SponsorPfizerEnrollment24Advanced/Metastatic Solid Tumors

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a Phase 1b, open label, multi center, multi-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended dose for phase 2 (RP2D) investigations of PF- 05082566 in combination with KW-0761 (mogamulizumab) in patients with advanced solid tumors. Once the MTD of PF-05082566 administered in combination with KW-0761 is estimated (dose finding), one or more expansion cohorts of patients with selected advanced solid tumors (dose-expansion ) will be enrolled to further characterize the combination in term of safety profile, anti tumor activity, pharmacokinetics, pharmacodynamics and biomarkers modulation.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Dale R Shepard, MD, PhD
The Cleveland Clinic
Principal Investigator
clinicaltrials.gov ↗
Esra E Cohen, MD
University of California, San Diego
Principal Investigator
clinicaltrials.gov ↗
Michael J Pishvaian, MD, PhD
Georgetown University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Pfizer CT.gov Call Center
Pfizer
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Uc San Diego Medical Center - la Jolla(thornton Hospital)
La Jolla, California, United States
Uc San Diego Moores Cancer Center
La Jolla, California, United States
University of California / San Diego Moores Cancer Center
La Jolla, California, United States
University of California San Diego Moores Cancer Center
La Jolla, California, United States
Uc San Diego Medical Center - Hillcrest
San Diego, California, United States
Georgetown University
Washington D.C., District of Columbia, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Henry Ford Hospital
Detroit, Michigan, United States
Henry Ford Hospital Research Pharmacy
Detroit, Michigan, United States
Unc Cancer Hospital Infusion Pharmacy
Chapel Hill, North Carolina, United States
Unc Hospitals, University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, United States
Sanford Cancer Center
Sioux Falls, South Dakota, United States
Sanford Research
Sioux Falls, South Dakota, United States
Sanford Usd Medical Center
Sioux Falls, South Dakota, United States
Tennessee Oncology, Pllc
Gallatin, Tennessee, United States
Tennessee Oncology, Pllc
Nashville, Tennessee, United States
the Sarah Cannon Research Institute
Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

KW-0761PF-05082566

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2015
Primary completion: 30 Sept 2017
Completion: 31 Oct 2017
Last update posted: 27 Feb 2019
Registered enrollment: 24
Registry id: NCT02444793

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.